

Distinct Populations of Immune-Suppressive Macrophages and Myeloid-Derived Suppressor Cells in Cancer

Cell Reports

33, 108571

DOI: [10.1016/j.celrep.2020.108571](https://doi.org/10.1016/j.celrep.2020.108571)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tumor-Associated Macrophagesâ€™ Implications for Molecular Oncology and Imaging. <i>Biomedicines</i> , 2021, 9, 374.	1.4	10
2	Inflammation-Induced Tumorigenesis and Metastasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5421.	1.8	88
3	Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy. <i>Cells</i> , 2021, 10, 1170.	1.8	31
4	Turning enemies into alliesâ€™ reprogramming tumor-associated macrophages for cancer therapy. <i>Med</i> , 2021, 2, 666-681.	2.2	17
5	Single-Cell Cloning of Breast Cancer Cells Secreting Specific Subsets of Extracellular Vesicles. <i>Cancers</i> , 2021, 13, 4397.	1.7	19
6	<i>Bundibugyo ebolavirus</i> Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling. <i>MBio</i> , 2021, 12, e0151721.	1.8	12
8	Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. <i>Cancer Discovery</i> , 2021, 11, 2693-2706.	7.7	89
9	Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 5590.	1.7	0
10	TGF-Î² orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1583-1596.	2.0	12
11	Myeloid Cellâ€™Derived Oxidized Lipids and Regulation of the Tumor Microenvironment. <i>Cancer Research</i> , 2022, 82, 187-194.	0.4	14
12	Comprehensive Molecular Analyses of a Macrophages-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and LASSO Algorithm. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
13	Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients. <i>Frontiers in Immunology</i> , 2021, 12, 809826.	2.2	8
14	Cellular architecture of human brain metastases. <i>Cell</i> , 2022, 185, 729-745.e20.	13.5	69
15	Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective. <i>Cancers</i> , 2022, 14, 510.	1.7	7
16	Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. , 2022, 235, 108114.		13
17	Emerging Roles of Myeloid-Derived Suppressor Cells in Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 798320.	1.6	18
18	Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 68.	3.5	115
19	Therapeutic Approaches Targeting Proteins in Tumor-Associated Macrophages and Their Applications in Cancers. <i>Biomolecules</i> , 2022, 12, 392.	1.8	6

#	ARTICLE	IF	CITATIONS
20	S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration and Invasion of Cancer Cells via Akt and p38 MAPK Pathways. <i>American Journal of Pathology</i> , 2022, 192, 536-552.	1.9	14
22	Specific inflammatory osteoclast precursors induced during chronic inflammation give rise to highly active osteoclasts associated with inflammatory bone loss. <i>Bone Research</i> , 2022, 10, 36.	5.4	15
23	In vivo imaging of microenvironmental and anti-PD-L1-mediated dynamics in cancer using S100A8/S100A9 as an imaging biomarker. <i>Neoplasia</i> , 2022, 28, 100792.	2.3	2
24	PD-1H Expression Associated With CD68 Macrophage Marker Confers an Immune-Activated Microenvironment and Favorable Overall Survival in Human Esophageal Squamous Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 777370.	1.6	2
25	Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies (Review). <i>Oncology Letters</i> , 2022, 23, 196.	0.8	4
27	The possible drug for cancer and metastasis prevention. <i>Future Drug Discovery</i> , 0, , .	0.8	0
28	Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
29	<scp>GM-CSF</scp>-induced hematopoietic dysregulation in the progression of solid tumors. <i>FEBS Open Bio</i> , 2022, 12, 1268-1285.	1.0	13
30	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. <i>Life Science Alliance</i> , 2022, 5, e202101316.	1.3	2
31	The Good and the Bad: Monocytes and Macrophages Diverse Functions in Inflammation. <i>Cells</i> , 2022, 11, 1979.	1.8	39
32	Dysregulated metabolism: A friend-to-foe skewer of macrophages. <i>International Reviews of Immunology</i> , 2023, 42, 287-303.	1.5	11
34	Immunotherapy: Reshape the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	77
35	Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets. <i>Cancer Research</i> , 2022, 82, 4274-4287.	0.4	11
36	IL-4-activated C/EBP β is involved in alveolar macrophage polarization towards the M2 phenotype during pulmonary fibrosis induced by single-walled carbon nanotubes. <i>Environmental Science: Nano</i> , 2022, 9, 4233-4248.	2.2	3
37	Targeting tumour-reprogrammed myeloid cells: the new battleground in cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2023, 45, 163-186.	2.8	14
38	Interleukin-22 protects from endotoxemia by inducing suppressive F4/80+Ly6ChiLy6Clow cells population. <i>BMC Immunology</i> , 2022, 23, .	0.9	1
39	Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
40	Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , OF1-OF10.	1.1	0

#	ARTICLE	IF	CITATIONS
41	Construction of a tumor immune infiltration macrophage signature for predicting prognosis and immunotherapy response in liver cancer. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
42	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
43	Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure. <i>Journal of Hepatology</i> , 2023, 78, 558-573.	1.8	15
44	Protein kinase C δ 1 mediates immunosuppression in lung adenocarcinoma. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	6
45	Comparison of monocytic cell lines U937 and THP-1 as macrophage models for in vitro studies. <i>Biochemistry and Biophysics Reports</i> , 2022, 32, 101383.	0.7	8
46	Tumor associated macrophage in HPV+ tumors: Between immunosuppression and inflammation. <i>Seminars in Immunology</i> , 2023, 65, 101671.	2.7	9
47	Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2023, 23, 173-188.	12.8	37
48	Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
49	Inflammation driven metabolic regulation and adaptation in macrophages. <i>Clinical Immunology</i> , 2023, 246, 109216.	1.4	7
50	Targeting macrophages: a novel treatment strategy in solid tumors. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	14
51	Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
52	Screening and identifying a novel M-MDSCs-related gene signature for predicting prognostic risk and immunotherapeutic responses in patients with lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
53	Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. <i>Cell Reports Medicine</i> , 2023, 4, 100916.	3.3	10
54	Myeloid-Derived Suppressor Cells in Cancer and COVID-19 as Associated with Oxidative Stress. <i>Vaccines</i> , 2023, 11, 218.	2.1	4
55	Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions. , 2023, 244, 108370.		2
56	Redox phospholipidomics discovers pro-ferroptotic death signals in A375 melanoma cells in vitro and in vivo. <i>Redox Biology</i> , 2023, 61, 102650.	3.9	8
57	S100A8 and S100A9 in Cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188891.	3.3	10
59	Therapeutic targeting of tumour myeloid cells. <i>Nature Reviews Cancer</i> , 2023, 23, 216-237.	12.8	49

#	ARTICLE	IF	CITATIONS
60	Beta glucan as an immune stimulant in tumor microenvironment – Insight into lessons and promises from past decade. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123617.	3.6	7
61	Reprogramming the tumor microenvironment leverages CD8+ T cell responses to a shared tumor/self antigen in ovarian cancer. <i>Molecular Therapy - Oncolytics</i> , 2023, 28, 230-248.	2.0	4
62	Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. <i>Nature Communications</i> , 2023, 14, .	5.8	29
63	S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. <i>Cancer Research Communications</i> , 2023, 3, 420-430.	0.7	3
64	<scp>S100A9</scp> promotes tumor-associated macrophage for <scp>M2</scp> macrophage polarization to drive human liver cancer progression: An in vitro study. <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 345-353.	0.8	3
65	Functional states of myeloid cells in cancer. <i>Cancer Cell</i> , 2023, 41, 490-504.	7.7	29
66	The role of myeloid derived suppressor cells in musculoskeletal disorders. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
67	The role of myeloid-derived immunosuppressive cells in cardiovascular disease. <i>International Immunopharmacology</i> , 2023, 117, 109955.	1.7	1
68	Chronic adrenergic stress and generation of <scp>myeloid-derived</scp> suppressor cells: Implications for cancer immunotherapy in dogs. <i>Veterinary and Comparative Oncology</i> , 2023, 21, 159-165.	0.8	2
69	Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
70	Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology. <i>Journal of Immunology</i> , 2023, 210, 1183-1197.	0.4	8
73	Cancer and the science of innate immunity. , 2024, , 61-90.e11.		0
89	In vitro generation of murine myeloid-derived suppressor cells from hematopoietic progenitor cells. <i>Methods in Cell Biology</i> , 2024, , 159-172.	0.5	0
91	Myeloid-derived suppressor cells in cancer and cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 147-164.	12.5	1